Savara announces new data in two poster presentations at ATS Conference 2025

Savara (SVRA) announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden and improves health-related quality of life outcomes in patients with aPAP. ATS 2025 Posters: Poster Title: Molgramostim Reduces Surfactant Burden and Number of Whole Lung Lavage Procedures in Patients with Autoimmune Pulmonary Alveolar Proteinosis: Results From the IMPALA-2 Phase 3 Clinical Trial. Summary: Molgramostim reduced surfactant burden as measured by ground-glass opacification scores, a radiological measure of surfactant burden. The mean reduction in GGO score from baseline to Week 24 was greater in the molgramostim group than in the placebo group; Fewer patients in the molgramostim group required rescue whole lung lavages compared with placebo. During the 48-week double-blind treatment period, 6 patients in the molgramostim group underwent a total of 15 WLLs and 11 patients in the placebo group underwent a total of 24 WLLs. Poster Title: The Effects of Molgramostim on Respiratory Health-related Quality of Life and Patient-reported Outcomes in Patients with Autoimmune Pulmonary Alveolar Proteinosis. Summary: Molgramostim showed benefit on measures of health-related quality of life and patients’ assessment of breathing problems and physical activity, including changes from baseline in St. George’s Respiratory Questionnaire Impact and Symptom scores, the EuroQol 5 Dimensions, 5 Levels, Patient Global Impression of Severity, and Patient Global Impression of Change at Weeks 24 and 48, which were included as exploratory endpoints in the trial; Molgramostim improved respiratory HRQoL as measured by changes from baseline to Week 24 in SGRQ Impact and Symptom scores compared with placebo, and the EQ-5D-5L, a generic HRQoL instrument comprised of a short descriptive system questionnaire that allows patients to rate their health across 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Odds ratios of responses on the EQ-5D-5L numerically favored the molgramostim group on 3 of the 5 dimensions at Weeks 24 and 48; Molgramostim reduced the severity of breathing problems, as assessed by PGIS, at both Weeks 24 and 48. Additionally, more molgramostim patients reported improvements in overall change in daily physical activity level, as measured by more patients assessing themselves as “Much better” or “A little better” compared with placebo at Week 24 and Week 48